Clinical Trials Browser

Inflammatory Breast Neoplasms

NCT01036087 2023-03-30

Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

Phase 2 Completed

47 enrolled 13 charts

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00193206 2021-11-23

Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer

Phase 2 Completed

123 enrolled 8 charts

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00464646 2021-10-25

Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer

Phase 2 Completed

105 enrolled 17 charts

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT02682693 2021-02-02

GeparX

Phase 2 Completed

780 enrolled

Breast

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

NCT00820547 2019-10-22

Beverly1

Phase 2 Completed

100 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

NCT00957125 2016-09-08

PROMIX

Phase 2 Unknown

151 enrolled

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00756470 2014-11-17

Phase II Neoadjuvant in Inflammatory Breast Cancer

Phase 2 Terminated

15 enrolled 10 charts

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00072319 2013-03-04

Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer

Phase 2 Completed

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT01641406 2012-07-16

NACprotocol

Phase 2 Unknown

60 enrolled

Breast

Breast Carcinoma In Situ, Carcinoma, Lobular, Inflammatory Breast Neoplasms

NCT00398489 2010-11-09

Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery

Phase 2 Unknown

94 enrolled

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00162812 2008-07-18

TOP

Phase 2 Terminated

338 enrolled

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

Clinical Trials

PELICAN

Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer

Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer

GeparX

Beverly1

PROMIX

Phase II Neoadjuvant in Inflammatory Breast Cancer

Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer

NACprotocol

Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery

TOP